JP2015528441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528441A5 JP2015528441A5 JP2015526733A JP2015526733A JP2015528441A5 JP 2015528441 A5 JP2015528441 A5 JP 2015528441A5 JP 2015526733 A JP2015526733 A JP 2015526733A JP 2015526733 A JP2015526733 A JP 2015526733A JP 2015528441 A5 JP2015528441 A5 JP 2015528441A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- subject
- use according
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 69
- 239000002502 liposome Substances 0.000 claims description 63
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 35
- 235000012000 cholesterol Nutrition 0.000 claims description 20
- 229910052724 xenon Inorganic materials 0.000 claims description 19
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 18
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 18
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 230000000638 stimulation Effects 0.000 claims description 15
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 12
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 12
- 239000002577 cryoprotective agent Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 238000002604 ultrasonography Methods 0.000 claims description 11
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- 230000001732 thrombotic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 79
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 22
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 description 5
- 229940012999 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) Drugs 0.000 description 5
- -1 PEG2000-DPPE Chemical compound 0.000 description 4
- 239000007789 gas Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 2
- 238000010943 off-gassing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682130P | 2012-08-10 | 2012-08-10 | |
| US61/682,130 | 2012-08-10 | ||
| CN201210356929.9A CN103565745A (zh) | 2012-08-10 | 2012-09-21 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| CN201210356929.9 | 2012-09-21 | ||
| PCT/US2013/054349 WO2014026117A2 (en) | 2012-08-10 | 2013-08-09 | Neuroprotective liposome compositions and methods for treatment of stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528441A JP2015528441A (ja) | 2015-09-28 |
| JP2015528441A5 true JP2015528441A5 (OSRAM) | 2016-09-29 |
| JP6297040B2 JP6297040B2 (ja) | 2018-03-20 |
Family
ID=50039028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526733A Active JP6297040B2 (ja) | 2012-08-10 | 2013-08-09 | 脳卒中の治療のための神経保護リポソーム組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10369103B2 (OSRAM) |
| EP (2) | EP2882422B1 (OSRAM) |
| JP (1) | JP6297040B2 (OSRAM) |
| CN (2) | CN103565745A (OSRAM) |
| AU (1) | AU2013299453B2 (OSRAM) |
| CA (2) | CA3132444C (OSRAM) |
| WO (1) | WO2014026117A2 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| EP4082552B1 (en) | 2013-03-15 | 2026-05-06 | The Board of Regents of the University of Texas System | Liquids rich in noble gas and methods of their preparation and use |
| US10456483B2 (en) | 2014-12-03 | 2019-10-29 | University Of Cincinnati | Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease |
| US10500227B2 (en) * | 2014-12-03 | 2019-12-10 | University Of Cincinnati | Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease |
| JP6622822B2 (ja) * | 2015-06-23 | 2019-12-18 | ノビリス セラピューティクス インコーポレイテッド | 希ガス組成物を用いた治療的な免疫調節 |
| EP3158992A1 (en) * | 2015-10-21 | 2017-04-26 | Universität Heidelberg | Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules |
| CZ307851B6 (cs) * | 2017-02-14 | 2019-06-26 | Ústav experimentální medicíny AV ČR, v. v. i. | Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění |
| JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
| EP3628309A1 (en) | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| JP7716076B2 (ja) * | 2021-02-04 | 2025-07-31 | 学校法人産業医科大学 | 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法 |
| JP2022144013A (ja) * | 2021-03-18 | 2022-10-03 | 橋本電子工業株式会社 | 抗血栓リポソーム |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4162282A (en) | 1976-04-22 | 1979-07-24 | Coulter Electronics, Inc. | Method for producing uniform particles |
| US4310505A (en) | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
| US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| IL79559A0 (en) | 1986-07-29 | 1986-10-31 | Univ Ramot | Contrast agents for nmr medical imaging |
| US4728578A (en) | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5228446A (en) | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
| WO1993020802A1 (en) | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| US5858399A (en) | 1992-04-09 | 1999-01-12 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| JP3746293B2 (ja) | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | 生物製剤のインビボ送達の方法とそのための組成物 |
| US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US6123919A (en) | 1994-04-08 | 2000-09-26 | The Trustees Of Princeton University | Magnetic resonance imaging using hyperpolarized noble gases |
| US5545396A (en) | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| WO1997015311A1 (fr) | 1995-10-20 | 1997-05-01 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Composition a base de monoxyde d'azote en tant que medicament |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| CA2263705C (en) | 1996-08-19 | 2007-12-04 | Nancy Smyth-Templeton | Novel sandwich liposome complexes comprising a biologically active agent |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US6548047B1 (en) * | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US6050444A (en) | 1998-07-22 | 2000-04-18 | Sugg; James Wesley | Consumable beverage dispenser with one-way valve |
| DE19910986C2 (de) | 1999-03-11 | 2001-06-07 | Aga Ab | Verwendung von Xenon bei der Behandlung von Neurointoxikationen |
| GB9913677D0 (en) | 1999-06-11 | 1999-08-11 | Imperial College | Formulation |
| DE19933704A1 (de) | 1999-07-19 | 2001-01-25 | Michael Georgieff | Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration |
| GB9917822D0 (en) | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| DE10054563A1 (de) | 2000-11-03 | 2002-05-16 | Messer Griesheim Gmbh | Verfahren und Vorrichtung zur Betonherstellung |
| AU2002220881A1 (en) | 2000-12-04 | 2002-06-18 | Uws Ventures Limited | Noble gas complexes |
| ES2243350T3 (es) | 2001-01-31 | 2005-12-01 | Bracco International B.V. | Agente de contraste liofizable que comprende microburbujas de gas. |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| DE60236520D1 (de) | 2001-08-16 | 2010-07-08 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
| US7202089B2 (en) | 2001-09-14 | 2007-04-10 | Alan Kleinfeld | Early diagnosis of stroke |
| GB0209998D0 (en) | 2002-05-01 | 2002-06-12 | Protexeon Ltd | Use |
| CN1668315A (zh) * | 2002-06-12 | 2005-09-14 | 梅瑟·格里斯海姆有限公司 | 使用含氙气体进行脑保护 |
| DE10328272A1 (de) | 2002-06-22 | 2004-01-15 | Messer Griesheim Gmbh | Medikament mit Xenon und NO |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1521598A1 (de) | 2002-07-05 | 2005-04-13 | Air Liquide Deutschland GmbH | Xenon enthaltendes adjuvans |
| GB0218153D0 (en) | 2002-08-05 | 2002-09-11 | Ic Innovations Ltd | An analgesic agent for newborn or retal subjects |
| DE10336768B4 (de) | 2002-08-10 | 2010-09-09 | Air Liquide Deutschland Gmbh | Medikament zur Verbesserung der Sauerstoffutilation |
| DE10336778B4 (de) | 2002-08-10 | 2010-09-16 | Air Liquide Deutschland Gmbh | Stabilisierung eines Patienten mit einem xenonhaltigen Gas |
| JP2006512906A (ja) | 2002-09-28 | 2006-04-20 | マサチューセッツ インスティチュート オブ テクノロジー | インフルエンザ治療剤 |
| WO2004047768A2 (en) | 2002-11-26 | 2004-06-10 | Seacoast Neuroscience, Inc. | Buoyant polymer particles delivering therapeutic agents |
| WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
| FR2849779B1 (fr) | 2003-01-15 | 2006-07-14 | Air Liquide Sante Sa | Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques |
| US7198179B2 (en) | 2003-02-25 | 2007-04-03 | Therox, Inc. | System for storing and dispensing a gas-solubilized product |
| US20060019868A1 (en) | 2004-01-30 | 2006-01-26 | Pendharkar Sanyog M | Hemostatic compositions and devices |
| AU2004280118B2 (en) | 2003-10-10 | 2009-01-15 | Imperial Innovations Limited | Use of xenon with hypothermia for treating neonatal asphyxia |
| EP1552840A1 (en) | 2004-01-07 | 2005-07-13 | Aga Ab | Use of a xenon/carbon monoxide mixture for the protection of cells |
| GB0418540D0 (en) | 2004-08-19 | 2004-09-22 | Protexeon Ltd | Use |
| EP1714642A1 (en) * | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
| AU2005332157A1 (en) | 2005-05-23 | 2006-11-30 | Mebiopharm Co., Ltd., | Method of producing liposomes containing gas enclosed therein |
| JP2009536663A (ja) | 2006-05-09 | 2009-10-15 | コルゲート・パーモリブ・カンパニー | 口腔ケア措置 |
| US7976743B2 (en) * | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
| US20080187605A1 (en) | 2007-02-02 | 2008-08-07 | Olney John W | Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems |
| US9814672B2 (en) * | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
| EP1980260A1 (en) | 2007-04-10 | 2008-10-15 | Nicholas Peter Franks | Use of hyperbaric conditions to provide neuroprotection |
| US8435569B2 (en) | 2007-04-30 | 2013-05-07 | Nnoxe Pharmaceutiques Inc. | Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon |
| ITMI20071031A1 (it) | 2007-05-22 | 2008-11-23 | Acetilene & Deriv Ati Siad Spa | Uso di xenon per la protezione di organi da danno ischemico |
| EP2229147A2 (en) * | 2007-12-03 | 2010-09-22 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| JP2011506432A (ja) | 2007-12-10 | 2011-03-03 | エピターゲット・アーエス | 非ラメラ形成脂質を含む音響感受性薬物送達粒子 |
| CL2007003772A1 (es) | 2007-12-21 | 2008-04-25 | Vulco Sa | Procedimiento para la fabricacion de un mandril flexible de poliuretano, que contiene un alma metalica que comprende recubrir con goma un alma metalica, aplicar desmoldante, precalentar el conjunto, curar el poliuretano y enfriar el codo. |
| US8618056B2 (en) * | 2007-12-22 | 2013-12-31 | Cuthbert O. Simpkins | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| ES2758830T3 (es) | 2008-11-10 | 2020-05-06 | Moleac Pte Ltd | Terapia combinada para el tratamiento de pacientes con trastornos neurológicos e infarto cerebral |
| EP2391341A4 (en) * | 2009-01-30 | 2012-05-09 | Cuthbert O Simpkins | REVIVAL LIQUID |
| FR2944969B1 (fr) | 2009-04-29 | 2011-08-26 | Air Liquide | Utilisation de n2o gazeux dans le traitement des douleurs chroniques |
| CN102625658B (zh) | 2009-05-13 | 2015-01-28 | 锡德克斯药物公司 | 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法 |
| US10130689B2 (en) * | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
| US8974818B2 (en) | 2010-01-20 | 2015-03-10 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
| FR2956323B1 (fr) | 2010-02-15 | 2013-12-20 | Air Liquide | Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques |
| CN103079599B (zh) | 2010-08-09 | 2017-05-10 | 博莱科瑞士股份有限公司 | 靶向气体填充微囊 |
| WO2012096697A1 (en) | 2011-01-14 | 2012-07-19 | Simpkins Cuthbert O | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| US20130247924A1 (en) | 2012-03-23 | 2013-09-26 | Mark Scatterday | Electronic cigarette having a flexible and soft configuration |
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
-
2012
- 2012-09-21 CN CN201210356929.9A patent/CN103565745A/zh active Pending
- 2012-09-21 CN CN201910643063.1A patent/CN110464709A/zh active Pending
-
2013
- 2013-08-09 AU AU2013299453A patent/AU2013299453B2/en active Active
- 2013-08-09 CA CA3132444A patent/CA3132444C/en active Active
- 2013-08-09 JP JP2015526733A patent/JP6297040B2/ja active Active
- 2013-08-09 EP EP13828100.1A patent/EP2882422B1/en active Active
- 2013-08-09 CA CA2881096A patent/CA2881096C/en active Active
- 2013-08-09 EP EP21170435.8A patent/EP3932394B1/en active Active
- 2013-08-09 WO PCT/US2013/054349 patent/WO2014026117A2/en not_active Ceased
- 2013-08-09 US US14/420,429 patent/US10369103B2/en active Active
-
2019
- 2019-06-26 US US16/453,252 patent/US10973764B2/en active Active
-
2021
- 2021-04-13 US US17/229,627 patent/US11872312B2/en active Active
-
2023
- 2023-12-14 US US18/540,656 patent/US20240398708A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5421322B2 (ja) | 線維化抑制のための薬物担体および薬物担体キット | |
| Szebeni et al. | Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome | |
| JP5437790B2 (ja) | 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物 | |
| CN1102045C (zh) | 新的含类脂和稳定剂的组合物 | |
| JP6297040B2 (ja) | 脳卒中の治療のための神経保護リポソーム組成物および方法 | |
| US20100196284A1 (en) | Ultrasound Imaging with Targeted Microbubbles | |
| CN104884065A (zh) | 治疗癌症的方法 | |
| US11439688B2 (en) | Synthetic platelets | |
| KR20090130081A (ko) | 2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법 | |
| CN115427064A (zh) | 使用基于脂质结合蛋白的复合物治疗急性病况的方法 | |
| CN117120028A (zh) | 使用载剂靶向递送治疗剂的组合物和方法 | |
| Kim et al. | Polymer lung surfactants | |
| CN117295518A (zh) | 使用免疫治疗剂的治疗的增强 | |
| WO2018071837A1 (en) | Radiofrequency field hyperthermia and solid tumor immunomodulation | |
| CN107708742A (zh) | 诊断治疗用气泡制剂(tb)及其使用方法 | |
| JP2008050375A (ja) | 線維化抑制のための薬物担体および薬物担体キット | |
| US20230181759A1 (en) | Compositions for treatment of viral respiratory infections and methods of use thereof | |
| CN108883068A (zh) | 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法 | |
| WO2005004914A1 (ja) | NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法 | |
| WO2017070338A1 (en) | Methods and compositions for treating lung disease of prematurity | |
| CN116115770A (zh) | 一种微环境重塑中药纳米气弹及其制备方法和应用 | |
| JP2024528010A (ja) | 気管支肺異形成症（ｂｐｄ）及びｂｐｄ関連肺高血圧症の治療のための組成物及び方法 | |
| US20250332183A1 (en) | Compositions and methods for the stimulation of intermediate macrophages and treatments therewith | |
| EP4504233A1 (en) | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes | |
| JP2025538488A (ja) | ペプチド修飾されたリポソーム用凍結乾燥緩衝液 |